Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors

Next Previous
Search
Trial Profile

An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simurosertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Takeda; Takeda Oncology

    • Most Recent Events

    • 25 Sep 2021 Results of a Pop PK analysis characterizing sources of variability on PK of TAK-931 in adult patients with advanced solid tumors ; using data from three clinical studies: NCT02699749, NCT03261947 and NCT03708211 published in the Journal of Clinical Pharmacology
    • 14 Jan 2020 Status changed from active, no longer recruiting to completed.
    • 29 Oct 2019 Planned End Date changed from 13 Mar 2020 to 2 Feb 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top